Bronchodilators Market - Forecast(2024 - 2030)

Report Code: HCR 28046 Report Format: PDF + Excel

Bronchodilators Market Overview

Bronchodilators Market size is forecast to reach $3.7 billion by 2026, growing at a CAGR of 6.3% during the forecast period 2021-2026. Bronchodilators relaxes muscles around the airways and open the airway to let more air move in and out of the lungs. They are used to reduce the mucus from the lungs and also have effects on mucociliary clearance. It is also used in the treatment of obstructive lung disease by relaxing and widening the bronchi. It treats asthma and chronic pulmonary diseases. Bronchodilators are administered through nebulizer to the patients who are sufferings from chronic respiratory disorders as they are used to reduce the mucus from the lungs. Increasing prevalence of pulmonary disorders and growing technological advancements are the major factors driving the growth of the market. Growing government initiatives for creating awareness among population and growing funding by government organizations is set to further enhance the overall market development of the Bronchodilators Market for the period 2021-2026.

Report Coverage

The report: Bronchodilators Market Forecast (2021-2026), by Industry ARC, covers an in-depth analysis of the following segments of the Bronchodilators Market.

By Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others.
By Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, and Combination Drug.
By Route of Administration: Oral, Injection, and Inhaler.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific ((APAC (China, Japan India, South Korea, Australia, and New Zealand, and Rest of APAC)), South America (Brazil, Argentina, and Rest of South America), and Rest of the World ((RoW) (Middle East, and Africa))

Key Takeaways

  • North America dominated the Bronchodilators Market in 2020 owing to the increase in cystic fibrosis and increase in government initiatives towards increasing awareness regarding asthma and other chronic respiratory diseases. The Bronchodilators Market scope for different regions will be provided in the final report.
  • Increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease and increasing awareness of healthcare among population are likely to aid the market growth of the Bronchodilators Market.
  • Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Bronchodilators Market report.
  • Government regulation related to the efficacy & safety of the bronchodilators and side effects associated with the bronchodilators is poised to create hurdles for the Bronchodilators Market.

    Bronchodilators Market Revenue Share, By Geography, 2020(%)

    Bronchodilators Market
    For More Details on This Report - Request for Sample

Bronchodilators Market Segment Analysis – By Indication

Asthma held the largest share in the Bronchodilators Market in 2020 and is estimated to grow at a CAGR 5.7% during the forecast period 2026. This is attributed to the increasing prevalence of asthma around the world. According to an estimation done by Asthma and Allergy Foundation of America, asthma accounts for 9.8 million of hospital visits and around 1.8 million emergency department visits each year. Increasing adoption of smoking along with exposure to certain gases or fumes and to heavy amounts of smoke, pollution, and use of cooking fire without proper ventilation is increasing the chronic obstructive pulmonary diseases. Chronic Obstructive Pulmonary Disease are estimated to register the highest CAGR over the period 2021-2026.

Bronchodilators Market Segment Analysis – By Drug Type

Anticholinergics held the largest share in the Bronchodilators Market in 2020 and is estimated to grow at a CAGR 6.0% during the forecast period 2026. This is attributed to this that anticholinergics are available in both short acting form as well as long acting form. Anticholinergic bronchodilators block the parasympathetic nerves and enables the air passages to remain open. It is widely used to treat chronic obstructive pulmonary disease. The demand for combination drug is increasing owing to their properties of dilating air passages and making air flow easier. Combination Drugs are estimated to register the highest CAGR over the period 2021-2026.

Bronchodilators Market Segment Analysis – By Geography

North America dominated the Bronchodilators Market with a major share of 36.4% in 2020. This is attributed to the increase in cystic fibrosis and increasing government initiatives towards increasing awareness regarding asthma, and chronic respiratory disorders among others. Increasing awareness regarding treatment options, rising adoption of inhaled therapeutics along with the significant improvement in the healthcare sector is increasing the growth of the market in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the increase in respiratory disorder patient pool, increase in availability of drugs, and rise in demand of bronchodilators in the pharmaceutical sectors.

Bronchodilators Market Drivers

Increase in Prevalence of Pulmonary Disorders

Increase in prevalence of pulmonary disorders is increasing the growth of the Bronchodilators Market. This is attributed to the indoor and outdoor air pollution, occupational dust, inhaled tobacco smoke, child pneumonia, and genetic syndromes among others. The number of deaths owing to the pulmonary disorder increased with age sharply among people aged 70 and older & is likely to increase as the worldwide population ages. Wealthier countries have lower rates of pulmonary disorders owing to the fact that people have better access to health services and improved treatments. Thus, increasing the growth of the Bronchodilators Market during the forecast period 2021-2026.

Increasing Usage of Bronchodilators for the Treatment of Cystic Fibrosis

Increasing usage of bronchodilators for the treatment of cystic fibrosis is increasing the growth of the Bronchodilators Market. This is attributed to the fact that inhaled bronchodilators are prescribed for 8-% of people with cystic fibrosis to widen the airways and alleviate symptoms. Long inhaled as well as short inhaled bronchodilators are used to improve respiratory symptoms as they take effect in minutes and typically last for eight hours. Cystic Fibrosis patients take bronchodilators using a metered dose inhaler as it ensures that they are able to breathe in a full dose of their medications. Thus, increasing the growth of the Bronchodilators Market during the forecast period 2021-2026.

Bronchodilators Market Challenges

Government Regulation Related to the Efficacy & Safety of the Bronchodilators and Side Effects Associated with the Bronchodilators

Some of the factors that are set to impede the growth of the Bronchodilators Market are government regulation related to the efficacy & safety of the bronchodilators and side effects associated with the bronchodilators. Low awareness for these products along with the cost of treatment is set to hinder the growth of the market.

Bronchodilators Market Landscape

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Bronchodilators Market. In 2020, the Bronchodilators Market share is consolidated by the top ten players present in the market. Bronchodilators Market, top 10 companies are Novartis AG, Pfizer, Cipla Technologies, Teva Pharmaceuticals, Astra Zeneca Plc., GlaxoSmith, Hoffman Roche, Abbott Laboratories, and Vectura Group among others.

Acquisitions/Product Launches

  • In April 2019, Cipla Technologies partnered with Pulmatrix Inc. to develop a formulation for the treatment of allergic bronchodilators aspergillosis in patients suffering from asthma.

Relevant Reports

Report Code: HCR 78621

Report Code: HCR 1217

For more Lifesciences and Healthcare Market reports, please click here

1. Bronchodilators Market- Overview
    1.1 Definitions and Scope
2. Bronchodilators Market- Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Indication
    2.3 Key trends by Drug Type
    2.4 Key trends by Route of Administration
    2.5 Key trends by Geography
3. Bronchodilators Market– Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Bronchodilators Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Bronchodilators Market– Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Bronchodilators MarketForces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Bronchodilators Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Bronchodilators Market– By Indication(Market Size –$Million/$Billion)
    8.1 Asthma
    8.2 Chronic Obstructive Pulmonary Disease
    8.3 Others
9. Bronchodilators Market– By Drug Type (Market Size –$Million/$Billion)
    9.1 Sympathomimetics
    9.2 Anticholinergics
    9.3 Phosphodiesterase Inhibitor
    9.4 Combination Drug
10. Bronchodilators Market– By Route of Administration (Market Size –$Million/$Billion)
    10.1 Oral
    10.2 Injection
    10.3 Inhaler
11. Bronchodilators Market- By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Bronchodilators Market- Entropy
13. Bronchodilators Market– Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Bronchodilators Market– Key Company List by Country Premium Premium
15. Bronchodilators Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 ($M)
1.1 Asthma Market 2023-2030 ($M) - Global Industry Research
1.2 COPD Market 2023-2030 ($M) - Global Industry Research
2.Global BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 ($M)
2.1 Long Acting Bronchodilators Market 2023-2030 ($M) - Global Industry Research
2.2 Short Acting Bronchodilators Market 2023-2030 ($M) - Global Industry Research
3.Global BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 ($M)
3.1 Oral Market 2023-2030 ($M) - Global Industry Research
3.2 Parenteral Market 2023-2030 ($M) - Global Industry Research
4.Global BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 ($M)
4.1 Sympathomimetics Market 2023-2030 ($M) - Global Industry Research
4.2 Anticholinergics Market 2023-2030 ($M) - Global Industry Research
4.3 Phosphodiesterase Inhibitor Market 2023-2030 ($M) - Global Industry Research
4.4 Combination Drugs Market 2023-2030 ($M) - Global Industry Research
5.Global BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 (Volume/Units)
5.1 Asthma Market 2023-2030 (Volume/Units) - Global Industry Research
5.2 COPD Market 2023-2030 (Volume/Units) - Global Industry Research
6.Global BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 (Volume/Units)
6.1 Long Acting Bronchodilators Market 2023-2030 (Volume/Units) - Global Industry Research
6.2 Short Acting Bronchodilators Market 2023-2030 (Volume/Units) - Global Industry Research
7.Global BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 (Volume/Units)
7.1 Oral Market 2023-2030 (Volume/Units) - Global Industry Research
7.2 Parenteral Market 2023-2030 (Volume/Units) - Global Industry Research
8.Global BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 (Volume/Units)
8.1 Sympathomimetics Market 2023-2030 (Volume/Units) - Global Industry Research
8.2 Anticholinergics Market 2023-2030 (Volume/Units) - Global Industry Research
8.3 Phosphodiesterase Inhibitor Market 2023-2030 (Volume/Units) - Global Industry Research
8.4 Combination Drugs Market 2023-2030 (Volume/Units) - Global Industry Research
9.North America BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 ($M)
9.1 Asthma Market 2023-2030 ($M) - Regional Industry Research
9.2 COPD Market 2023-2030 ($M) - Regional Industry Research
10.North America BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 ($M)
10.1 Long Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
10.2 Short Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
11.North America BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 ($M)
11.1 Oral Market 2023-2030 ($M) - Regional Industry Research
11.2 Parenteral Market 2023-2030 ($M) - Regional Industry Research
12.North America BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 ($M)
12.1 Sympathomimetics Market 2023-2030 ($M) - Regional Industry Research
12.2 Anticholinergics Market 2023-2030 ($M) - Regional Industry Research
12.3 Phosphodiesterase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
12.4 Combination Drugs Market 2023-2030 ($M) - Regional Industry Research
13.South America BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 ($M)
13.1 Asthma Market 2023-2030 ($M) - Regional Industry Research
13.2 COPD Market 2023-2030 ($M) - Regional Industry Research
14.South America BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 ($M)
14.1 Long Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
14.2 Short Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
15.South America BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 ($M)
15.1 Oral Market 2023-2030 ($M) - Regional Industry Research
15.2 Parenteral Market 2023-2030 ($M) - Regional Industry Research
16.South America BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 ($M)
16.1 Sympathomimetics Market 2023-2030 ($M) - Regional Industry Research
16.2 Anticholinergics Market 2023-2030 ($M) - Regional Industry Research
16.3 Phosphodiesterase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
16.4 Combination Drugs Market 2023-2030 ($M) - Regional Industry Research
17.Europe BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 ($M)
17.1 Asthma Market 2023-2030 ($M) - Regional Industry Research
17.2 COPD Market 2023-2030 ($M) - Regional Industry Research
18.Europe BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 ($M)
18.1 Long Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
18.2 Short Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
19.Europe BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 ($M)
19.1 Oral Market 2023-2030 ($M) - Regional Industry Research
19.2 Parenteral Market 2023-2030 ($M) - Regional Industry Research
20.Europe BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 ($M)
20.1 Sympathomimetics Market 2023-2030 ($M) - Regional Industry Research
20.2 Anticholinergics Market 2023-2030 ($M) - Regional Industry Research
20.3 Phosphodiesterase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
20.4 Combination Drugs Market 2023-2030 ($M) - Regional Industry Research
21.APAC BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 ($M)
21.1 Asthma Market 2023-2030 ($M) - Regional Industry Research
21.2 COPD Market 2023-2030 ($M) - Regional Industry Research
22.APAC BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 ($M)
22.1 Long Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
22.2 Short Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
23.APAC BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 ($M)
23.1 Oral Market 2023-2030 ($M) - Regional Industry Research
23.2 Parenteral Market 2023-2030 ($M) - Regional Industry Research
24.APAC BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 ($M)
24.1 Sympathomimetics Market 2023-2030 ($M) - Regional Industry Research
24.2 Anticholinergics Market 2023-2030 ($M) - Regional Industry Research
24.3 Phosphodiesterase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
24.4 Combination Drugs Market 2023-2030 ($M) - Regional Industry Research
25.MENA BRONCHODILATORS MARKET, BY INDICATION Market 2023-2030 ($M)
25.1 Asthma Market 2023-2030 ($M) - Regional Industry Research
25.2 COPD Market 2023-2030 ($M) - Regional Industry Research
26.MENA BRONCHODILATORS MARKET, BY MODE OF ACTION Market 2023-2030 ($M)
26.1 Long Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
26.2 Short Acting Bronchodilators Market 2023-2030 ($M) - Regional Industry Research
27.MENA BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION Market 2023-2030 ($M)
27.1 Oral Market 2023-2030 ($M) - Regional Industry Research
27.2 Parenteral Market 2023-2030 ($M) - Regional Industry Research
28.MENA BRONCHODILATORS MARKET, BY DRUG TYPE Market 2023-2030 ($M)
28.1 Sympathomimetics Market 2023-2030 ($M) - Regional Industry Research
28.2 Anticholinergics Market 2023-2030 ($M) - Regional Industry Research
28.3 Phosphodiesterase Inhibitor Market 2023-2030 ($M) - Regional Industry Research
28.4 Combination Drugs Market 2023-2030 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Bronchodilators Market Revenue, 2023-2030 ($M)
2.Canada Bronchodilators Market Revenue, 2023-2030 ($M)
3.Mexico Bronchodilators Market Revenue, 2023-2030 ($M)
4.Brazil Bronchodilators Market Revenue, 2023-2030 ($M)
5.Argentina Bronchodilators Market Revenue, 2023-2030 ($M)
6.Peru Bronchodilators Market Revenue, 2023-2030 ($M)
7.Colombia Bronchodilators Market Revenue, 2023-2030 ($M)
8.Chile Bronchodilators Market Revenue, 2023-2030 ($M)
9.Rest of South America Bronchodilators Market Revenue, 2023-2030 ($M)
10.UK Bronchodilators Market Revenue, 2023-2030 ($M)
11.Germany Bronchodilators Market Revenue, 2023-2030 ($M)
12.France Bronchodilators Market Revenue, 2023-2030 ($M)
13.Italy Bronchodilators Market Revenue, 2023-2030 ($M)
14.Spain Bronchodilators Market Revenue, 2023-2030 ($M)
15.Rest of Europe Bronchodilators Market Revenue, 2023-2030 ($M)
16.China Bronchodilators Market Revenue, 2023-2030 ($M)
17.India Bronchodilators Market Revenue, 2023-2030 ($M)
18.Japan Bronchodilators Market Revenue, 2023-2030 ($M)
19.South Korea Bronchodilators Market Revenue, 2023-2030 ($M)
20.South Africa Bronchodilators Market Revenue, 2023-2030 ($M)
21.North America Bronchodilators By Application
22.South America Bronchodilators By Application
23.Europe Bronchodilators By Application
24.APAC Bronchodilators By Application
25.MENA Bronchodilators By Application
26.Abbott Laboratories, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.AstraZeneca plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Boehringer Ingelheim GmbH, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.F. Hoffmann-La Roche AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.GlaxoSmithKline plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Merck Co., Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Novartis AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Pfizer Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Teva Pharmaceutical Industries Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Vectura Group plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)